...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of bronchology & interventional pulmonology >Pleural Fluid for the Detection of Actionable Somatic Mutations Have We Struck Oil Yet?
【24h】

Pleural Fluid for the Detection of Actionable Somatic Mutations Have We Struck Oil Yet?

机译：检测可操作的体细胞突变的胸膜液体又击中了油？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Lung cancer is the leading cause of cancer-related mortality in both men and women, with an estimated 1.69 million deaths worldwide in 2015. Up to 15% of patients with non-small cell lung cancer (NSCLC) have malignant pleural effusion (MPE) at presentation and require pleural fluid drainage for management of dyspnea, in addition to diagnostic and staging purposes, and over 30% develop MPE at some stage during their illness. A significant percentage of lung tumors have been shown to carry actionable somatic mutations, each of which represents an opportunity for novel targeted or "personalized" therapy for NSCLC. This has created hope for a disease that carries high morbidity and mortality. Cutting-edge sequencing modalities provide a unique opportunity to investigate potentially targetable molecular aberrations in tumor-suppressor genes and oncogenes. Current American Society of Clinical Oncology guidelines recommend molecular analysis for all actionable somatic mutations to target therapy in patients with NSCLC. Pleural fluid drainage through thoracentesis is among the least invasive and most cost-effective methods of tissue acquisition for staging and diagnosis, when compared with bronchoscopic or surgical biopsy of the primary tumor or adjacent and distant tumor-infiltrated organs. For this reason, MPE has been considered as a potential source for oncogenic driver mutation testing-but key questions about its utility in this context remain.
机译：肺癌是男女癌症相关死亡率的主要原因，2015年估计全球179万人死亡。高达15％的非小细胞肺癌（NSCLC）具有恶性胸腔积液（MPE）在介绍和需要胸膜流体排水，除了诊断和分期目的外，还需要在疾病期间在某个阶段产生30％的MPE。已经显示出显着百分比的肺肿瘤可携带可操作的体细胞突变，每个突变代表新型针对性或“个性化”治疗的机会。这为患有高发病率和死亡率的疾病创造了希望。尖端测序方式提供了探讨肿瘤抑制基因和癌基因中潜在的靶向分子畸变的独特机会。目前美国临床肿瘤学会指导建议对NSCLC患者的所有可操作的体细胞突变推荐分子分析。通过胸腔面孔的胸腔流体引流是与原发性肿瘤或邻近肿瘤渗透器官的支气管镜或手术活组织检查相比的分期和诊断的至少侵袭性和组织采集方法中的最小侵入性和最具成本效益的方法。因此，MPE被认为是致癌驾驶员突变测试的潜在来源 - 但关于其在这种背景下的实用性的关键问题仍然存在。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号